lanly

in vivo pharmacology


Syngeneic Tumor Model

The homologous transplant tumor models that Lanli Biology has established include:

1. Subcutaneous Inoculation Model

 

Tumor type

Model

Bladder

MBT-2

Blood/Leukemia

C1498

Blood/Lymphoma

A20,E.G7-OVA,EL4,L5178-R (LY-R)

Blood/Myeloma

J558,MPC-11,P3X63Ag8U.1

Brain&Nerves

GL261 Red-Fluc,N1E-115,Neuro-2a

Breast

4T-1,EMT6,JC

Kidney

Renca

Colorectum

Colon-26,CT26.WT,MC-38

Liver

H22,Hepa 1-6

Lung

KLN 205,LL/2 (LLC1)

Prostate

RM-1

Pancreas

Pan02

Skin

B16/BL6,B16-F0,B16-F1,B16-F10,CloneM-3

Other

WEHI 164

 

2. Syngeneic Model

 

Luciferase labeling

MC38 Luc,4T1 Luc,RM-1 Luc,CT26. WT Luc,Hepa 1-6 Luc,Pan02 Luc,H22 Luc

Other

EMT6-hHER2,EMT6-hCD19,CT26.WT-OVA,CT26.WT-hEPCAM,CT26.WT-hGPC3,MC38-hHER2,MC38- hEPCAM,MC38-mCD47 KO, MC38-mCD47 KO/hCD47, B16-F10-OVA,A20-hCD20,B16-F10-SIY

 

3. In situ inoculation model, transfer model, etc.

Lanli Biology also provides in situ models, leukemia systemic tumor models, tumor metastasis models, etc. Please consult for details.info@lanlybio.com。